Skip to content

Biogen BIIB LUNSUMIO — Sales trigger gross sales threshold

Similar metrics at other companies

Boise Cascade logo
BCCLumber — Sales
$12.2M-3.9%
Vontier logo
VNTSales of products — Sales
$675M+2.6%
Vontier logo
VNTSales of services — Sales
$75.6M-9.0%
DXP Enterprises logo
DXPEAcquisition Sales — Sales
$40.75M+31.0%
Tarsus Pharmaceuticals, Inc. logo
TARSCommercial Sales Milestone Payments — Contractual milestone payment net sales
$102M0.0%
ECV
ECVTOther — Sales
$8.19M+2.6%

Other financials

Income statement

See full
Revenue$2.5B+1.9%
Gross profit$1.8B+0.8%
Operating income$610.7M
Net income$319.5M+32.8%
EPS (diluted)$2.15+31.1%

Balance sheet

See full
Cash & equivalents$3.4B+30.2%
Total debt$6.6B+34.7%
Total equity$18.7B+9.9%
Total assets$29.5B+5.2%

Cash flow

See full
Operating cash flow$645.5M+149%
CapEx$51.2M+38.0%
Free cash flow$594.3M+167%

Valuation

See full
Market cap$31.89B+72.3%
Enterprise value$35.07B+57.0%
P/E22.5×+10.4×
P/S3.2×+1.4×

Profitability

See full
Gross margin75.5%-0.1pp
Operating margin22.9%
Net margin14.3%-0.8pp
FCF margin24.4%-0.4pp

Returns & leverage

See full
Return on equity8%-1.2pp
Debt / equity0.4×+0.1×
Current ratio3.1×+1.6×

Where this comes from

Reported directly by Biogen in its filing.

Tagged under the XBRL concept biib:SalesTriggerGrossSalesThreshold.

The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biogen's lunsumio — sales trigger gross sales threshold.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biogen's LUNSUMIO — sales trigger gross sales threshold?
Biogen (BIIB) reported LUNSUMIO — sales trigger gross sales threshold of $350M in Q1 2026.
What does LUNSUMIO — sales trigger gross sales threshold mean?
This is a defined gross sales level that, when exceeded, triggers a specific contractual event or adjustment in the Lunsumio collaboration agreement. It serves as a key performance indicator for the commercial scale of the product. Monitoring this helps investors understand when the partnership enters a new tier of financial or operational engagement.